N@N

BioSante Pharmaceuticals, Inc. To Present at the Deutsche Bank Annual Health Care Conference

_{//health-fitness.news-articles.net/content/2011/ .. deutsche-bank-annual-health-care-conference.html}
^{Published in Health and Fitness on Wednesday, April 27th 2011 at 5:05 GMT by Market Wire}  

LINCOLNSHIRE, Ill.--([ BUSINESS WIRE ])--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the 36^th Annual Deutsche Bank Health Care Conference to be held at the InterContinental Hotel, Boston from May 2-4, 2011.

Phillip B. Donenberg, BioSantea™s senior vice president, finance & CFO, will speak on Tuesday May 3, 2011 at 4:10 pm EDT. He will provide an overview of the company, as well as an update on the LibiGel^® (testosterone gel) Phase III clinical development program.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSantea™s lead products include LibiGel^® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSantea™s first FDA-approved product is Elestrina" (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSantea™s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gela", a testosterone gel for male hypogonadism, for which an NDA has been filed with a PDUFA date of November 14, 2011, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: [ www.biosantepharma.com ].